Intensive Care Unit, Thumbay Hospital, Ajman, United Arab Emirates.
Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
Pan Afr Med J. 2022 Nov 9;43:129. doi: 10.11604/pamj.2022.43.129.35014. eCollection 2022.
The COVID-19 pandemic is arguably one of the greatest public health crises since the 1918 influenza pandemic. Although several vaccines have been approved and rolled out, effective antiviral treatment options are very limited. Here, we present a case of severe COVID-19 that failed to respond to the standard interventions and continued to deteriorate. On day 22 of his illness, after informed consent, the patient was administered 4000IU of erythropoietin (EPO) subcutaneously, in the hope of improving his O saturation. Positive response was observed in the patient within 24 hours. This prompted us to continued EPO treatment for a total of 42 days until full recovery and discharge. Our findings warrant further studies to ascertain the use of EPO in severe cases COVID-19.
新冠疫情是自 1918 年流感大流行以来最严重的公共卫生危机之一。尽管已经批准并推出了几种疫苗，但有效的抗病毒治疗选择非常有限。在这里，我们报告了一例严重的 COVID-19 病例，该病例对标准干预措施没有反应，病情继续恶化。在发病第 22 天，在获得知情同意后，患者皮下注射了 4000IU 的红细胞生成素（EPO），希望能提高他的血氧饱和度。在 24 小时内，患者出现了阳性反应。这促使我们继续进行 EPO 治疗，总共 42 天，直到完全康复并出院。我们的发现需要进一步研究，以确定 EPO 在严重 COVID-19 病例中的使用。
